Answers are grounded in this paper and cite their sources.
Systematic review assesses costs of anticoagulants like apixaban and rivaroxaban for thromboembolism prevention in COVID-19 patients.
COVID-19 is a multisymptomatic infectious viral disease, one of the main complications of which is excessive blood clot formation, which can lead to myocardial infarction and stroke. The aim of the study was to assess the cost aspects of market offers of medicines recommended for the prevention of excessive thrombosis in patients who have had COVID-19 and are prone to thrombosis. Materials and methods. To conduct the study, data from the State Register of Medicines of Ukraine, Compendium, and the Register of Wholesale Prices for Medicines. The data of the Protocol "Provision of medical care for the treatment of coronavirus disease (COVID-19)" has been systematized and summarized. Additionally, international recommendations for providing care to patients with COVID-19 were studied through Embase Global Health, Medline, PubMed. The following methods were used: systematic review, documentary, bibliographic, statistical, analytical, comparative, generalizing, informational. Results. In Ukraine, the protocol "Providing medical care for the treatment of coronavirus disease (COVID-19)" is in effect, which recommends that after COVID-19, patients with a risk of excessive thromboembolism continue anticoagulant therapy with oral anticoagulants, which include direct thrombin inhibitors (Dabigatran) and direct factor Xa inhibitors (Rivaroxaban, Apixaban). As a result of the conducted studies, it was found that the cost of a 30-day course of preventive treatment for a patient is: apixaban 2.5 mg - 1398.00 UAH; pradakasa 300 mg - 1523.40 UAH; xarelto 15 mg/20 mg - 1871.94 UAH. The cost of pharmacotherapy with apixaban 2.5 mg is the lowest compared to xarelto by 1.3 times. Conclusions. Prophylactic pharmacotherapy with oral anticoagulants for patients at risk of excessive thromboembolism after COVID-19 should lead to normalization of blood coagulation status and prevent thromboembolism
No takes yet. Share an insight, caveat, or question.
O. Semenov (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: